Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added. The drug is a generic version of Japan-based Fujifilm Toyama Chemical Co Ltd's Avigan tablets.
As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care, the company said.
Treatment duration is a maximum of 14 days and the total study duration will be a maximum for 28 days from randomisation, it added.
In the past few months, following the outbreak of Covid-19, multiple clinical trials have been initiated on such patients in China, Japan and in the US.
Pharmaceuticals Executive Vice President, Global R&D, Sushrut Kulkarni said the company is all geared up to immediately begin clinical trials on Favipiravir on Covid-19 patients in India.
"The clinical trial will let us know the efficacy of this molecule on Covid-19 patients. If the clinical trials are successful, Favipiravir could become a potential treatment for Covid-19 patients," he added.
Shares of Glenmark Pharmaceuticals
Ltd rose almost 9% on Thursday after they got an approval to conduct clinical trials with Favipiravir, seen as a potential treatment for Covid-19